Pulmonary Embolism

Clinical Trial Finder

Many patients with pulmonary embolism are interested in participating in the latest research regarding their condition. This Clinical Trial Finder can help you—or a loved one—easily find ongoing cardiovascular clinical research trials for which you might qualify. This list is a service of the U.S. National Institutes of Health called clinicaltrials.gov, a database of publicly and privately supported clinical studies.

Simply click on the trial below that interests you to learn how you might participate.

Validation of Different Risk Assessment Strategies in Normotensive Pulmonary Embolism

Condition:   Pulmonary Embolism.
Intervention:  
Sponsor:   Azienda Ospedaliera Cosenza
Not yet recruiting - verified July 2016

Retrospective Study of Acute Chest Pain in Extremely Critical Condition for More Than Ten Years

Conditions:   Acute Myocardial Infarction;   Pulmonary Embolism;   Aortic Dissection
Intervention:  
Sponsor:   Qilu Hospital
Recruiting - verified July 2016

A Non-interventional Study on Xarelto for Treatment of Venous Thromboembolism (VTE) and Prevention of Recurrent VTE in Patients With Active Cancer

Condition:   Venous Thrombosis and Pulmonary Embolism
Intervention:   Drug: Rivaroxaban (Xarelto, BAY 59-7939)
Sponsors:   Bayer;   Janssen Research & Development, LLC
Not yet recruiting - verified July 2016

Special Drug Use Investigation of Xarelto for Venous Thromboembolism (VTE)

Condition:   Venous Thromboembolism
Intervention:   Drug: Rivaroxaban (Xarelto, BAY59-7939)
Sponsor:   Bayer
Recruiting - verified July 2016

A Study of Rivaroxaban for Early Discharge of Low Risk Pulmonary Embolism From the Emergency Department

Condition:   Pulmonary Embolism
Interventions:   Drug: Rivaroxaban;   Drug: Standard-of-care
Sponsors:   Janssen Scientific Affairs, LLC;   Bayer
Recruiting - verified July 2016

A Study to Evaluate the Efficacy and Safety of Rivaroxaban Venous Thromboembolism (VTE) Prophylaxis in Ambulatory Cancer Participants

Condition:   Cancer
Interventions:   Drug: Rivaroxaban;   Drug: Placebo
Sponsors:   Janssen Research & Development, LLC;   Bayer
Recruiting - verified July 2016

Global Study Comparing a rivAroxaban-based Antithrombotic Strategy to an antipLatelet-based Strategy After Transcatheter aortIc vaLve rEplacement to Optimize Clinical Outcomes

Condition:   Transcatheter Aortic Valve Replacement
Interventions:   Drug: Rivaroxaban (Xarelto, BAY59-7939);   Drug: Acetylsalicylic acid;   Drug: Clopidogrel
Sponsors:   Bayer;   Janssen Research & Development, LLC
Recruiting - verified July 2016

Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Practice (Sweden)

Condition:   Acute Coronary Syndrome
Interventions:   Drug: Rivaroxaban (Xarelto, BAY59-7939);   Drug: Standard of care drugs
Sponsor:   Bayer
Recruiting - verified July 2016

Assessment of Radiolabeled rhAnnexin V-128 in Infective Endocarditis

Conditions:   Endocarditis;   Thrombosis
Intervention:   Other: 99mTc-Annexin V-128 SPECT
Sponsors:   Institut National de la Santé Et de la Recherche Médicale, France;   Advanced Accelerator Applications
Recruiting - verified July 2016

Early Post-Marketing Study of ELIQUIS (Apixaban) in Mexico

Conditions:   Deep Vein Thrombosis;   Pulmonary Embolism
Intervention:   Drug: Apixaban
Sponsor:   Bristol-Myers Squibb
Recruiting - verified July 2016

Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (UK)

Condition:   Pulmonary Embolism
Interventions:   Drug: Rivaroxaban (Xarelto, Bay59-7939);   Drug: Warfarin
Sponsor:   Bayer
Recruiting - verified July 2016

Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (Netherlands)

Conditions:   Venous Thrombosis;   Pulmonary Embolism;   Atrial Fibrillation;   Acute Coronary Syndrome
Interventions:   Drug: Rivaroxoban (Xarelto, Bay59-7939);   Drug: Standard of care
Sponsor:   Bayer
Recruiting - verified July 2016

Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (Germany)

Conditions:   Venous Thrombosis;   Pulmonary Embolism;   Atrial Fibrillation;   Acute Coronary Syndrome
Interventions:   Drug: Rivaroxaban (Xarelto, Bay59-7939);   Drug: Standard of care
Sponsor:   Bayer
Recruiting - verified July 2016

Comparison of Low and Intermediate Dose Low-molecular-weight Heparin to Prevent Recurrent Venous Thromboembolism in Pregnancy

Conditions:   Deep Venous Thrombosis;   Pulmonary Embolism
Interventions:   Drug: Low dose nadroparin;   Drug: Intermediate dose nadroparin;   Drug: Low dose enoxaparin;   Drug: Intermediate dose enoxaparin;   Drug: Low dose dalteparin;   Drug: Intermediate dose dalteparin;   Drug: Fixed low dose tinzaparin;   Drug: Intermediate dose tinzaparin
Sponsors:   Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA);   Netherlands Organisation for Scientific Research;   Aspen Pharma;   CHU of Saint Etienne (sponsor of the French part of the study)
Recruiting - verified July 2016

PRevention of End Stage Kidney Disease by Darbepoetin Alfa In Chronic Kidney Disease Patients With nondiabeTic Kidney Disease

Conditions:   Chronic Kidney Disease;   Diabetes
Intervention:   Drug: Darbepoetin alfa
Sponsors:   Translational Research Informatics Center, Kobe, Hyogo, Japan;   Showa University School of Medicine
Active, not recruiting - verified July 2016

Optimal Duration of Anticoagulation in Deep Venous Thrombosis

Conditions:   Deep Vein Thrombosis of Lower Limb;   Lower Extremity Deep Venous Thrombosis Recurrent
Intervention:   Drug: Sodium warfarin
Sponsor:   University of Padova
Completed - verified July 2016

Post-authorization Safety Study of Etoricoxib and Other Anti-inflammatory Therapies in European Patients With Ankylosing Spondylitis (MK-0663-163)

Condition:   Ankylosing Spondylitis
Intervention:  
Sponsor:   Merck Sharp & Dohme Corp.
Active, not recruiting - verified July 2016

Postmarketing Study of ORTHO EVRA (Norelgestromin and Ethinyl Estradiol Contraceptive Patch) in Relation to Venous Thromboembolism (Blood Clots), Stroke and Heart Attacks

Conditions:   Contraception;   Female Contraception
Interventions:   Drug: Monophasic or triphasic Oral contraceptive tablet;   Drug: Ortho Evra transdermal patch containing 6 mg NGMN/0.75 mg EE
Sponsors:   Johnson & Johnson Pharmaceutical Research & Development, L.L.C.;   Boston Collaborative Drug Surveillance Program
Completed - verified July 2016

Prospective Investigation of Pulmonary Embolism Diagnosis (PIOPED II)

Conditions:   Lung Diseases;   Pulmonary Embolism;   Venous Thromboembolism
Intervention:   Device: Tomography, X-ray Computed
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Completed - verified January 2008

Standard Therapy With or Without Dalteparin in Treating Patients With Advanced Breast, Lung, Colorectal, or Prostate Cancer

Conditions:   Breast Cancer;   Colorectal Cancer;   Lung Cancer;   Prostate Cancer;   Veno-occlusive Disease
Interventions:   Drug: dalteparin;   Drug: standard therapy
Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI)
Completed - verified July 2016